🇺🇸 FDA
Patent

US 12385010

Gene therapy for recessive dystrophic epidermolysis bullosa using genetically corrected autologous keratinocytes

granted A61KA61K48/0058A61K48/0075

Quick answer

US patent 12385010 (Gene therapy for recessive dystrophic epidermolysis bullosa using genetically corrected autologous keratinocytes) held by United States Government as represented by the Department of Veterans Affairs expires Mon Aug 07 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
United States Government as represented by the Department of Veterans Affairs
Grant date
Tue Aug 12 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Aug 07 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
17
CPC classes
A61K, A61K48/0058, A61K48/0075, A61K48/0091, A61P